Top

Published in:

01-03-2019 | Original Article

TP53 inactivation and expression of methylation-associated proteins in gastric adenocarcinoma with enteroblastic differentiation

Authors: Noboru Yatagai, Tsuyoshi Saito, Yoichi Akazawa, Takuo Hayashi, Yuka Yanai, Sho Tsuyama, Hiroya Ueyama, Takashi Murakami, Sumio Watanabe, Akihito Nagahara, Takashi Yao

Published in: Virchows Archiv | Issue 3/2019

Abstract

Gastric adenocarcinoma with enteroblastic differentiation (GAED) is a rare variant of aggressive adenocarcinoma. We demonstrated previously that GAED is genetically characterized by frequent TP53 mutation. In this study, we aimed to further clarify the mechanism of inactivation of TP53 in GAED in the light of promoter methylation of TP53, and expression of methylation-associated proteins such as Ten-eleven translocation (TET) 1 and 5-hydroxymethylcytosine (5-hmc) in addition to ATM mutations. We analyzed 51 cases of GAED. The ATM mutation was detected in only one case. Promoter methylation of TP53 was detected in 18% and frequency of loss of heterozygosity (LOH) at TP53 locus was 37.2%. Reduced TET1 expression was found in 29 cases (56.9%) and was significantly associated with advanced stage (p = 0.01), lymph node metastasis (p = 0.04), and macroscopic type (p = 0.01). Reduced 5-hmc expression was found in 28 cases (54.9%) and was significantly associated with advanced stage (p = 0.01), gender (p = 0.01), tumor location (p = 0.03), tumor size (p = 0.01), and lymph node metastasis (p = 0.01). Among 9 cases with TP53 promoter methylation, reduced expression of TET1 was observed in 6 cases, and reduced expression of 5-hmc was observed in 5 cases. Reduced expression of both TET1 and 5-hmc was significantly associated with adverse clinical outcomes. In summary, promoter methylation of TP53 is partly involved in loss of p53 expression. Aberrant methylation by reduced TET1 and 5-hmc may be involved in the development of aggressive GAED.

Available only for authorised users

Govender D, Ramdial PK, Clarke B, Chetty R (2004) Clear cell (glycogen-rich) gastric adenocarcinoma. Ann Diagn Pathol 8:69–73CrossRefPubMed

Ghotli ZA, Serra S, Chetty R (2007) Clear cell (glycogen rich) gastric adenocarcinoma: a distinct tubulo-papillary variant with a predilection for the cardia/gastro-oesophageal region. Pathology 39:466–469. https://doi.org/10.1080/00313020701569972 CrossRefPubMed

Matsunou H, Konishi F, Jalal RE, Yamamichi N, Mukawa A (1994) Alpha-fetoprotein-producing gastric carcinoma with enteroblastic differentiation. Cancer 73:534–540CrossRefPubMed

Murakami T, Yao T, Mitomi H, Morimoto T, Ueyama H, Matsumoto K, Saito T, Osada T, Nagahara A, Watanabe S (2016) Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases. Gastric Cancer 19:498–507. https://doi.org/10.1007/s10120-015-0497-9 CrossRefPubMed

Matsumoto K, Ueyama H, Matsumoto K, Akazawa Y, Komori H, Takeda T, Murakami T, Asaoka D, Hojo M, Tomita N, Nagahara A, Kajiyama Y, Yao T, Watanabe S (2016) Clinicopathological features of alpha-fetoprotein producing early gastric cancer with enteroblastic differentiation. World J Gastroenterol 22:8203–8210. https://doi.org/10.3748/wjg.v22.i36.8203 CrossRefPubMedPubMedCentral

Kodama T, Kameya T, Hirota T, Shimosato Y, Ohkura H, Mukojima T, Kitaoka H (1981) Production of alpha-fetoprotein, normal serum proteins, and human chorionic gonadotropin in stomach cancer: histologic and immunohistochemical analyses of 35 cases. Cancer 48:1647–1655CrossRefPubMed

Kinjo T, Taniguchi H, Kushima R, Sekine S, Oda I, Saka M, Gotoda T, Kinjo F, Fujita J, Shimoda T (2012) Histologic and immunohistochemical analyses of alpha-fetoprotein--producing cancer of the stomach. Am J Surg Pathol 36:56–65. https://doi.org/10.1097/PAS.0b013e31823aafec CrossRefPubMed

Ushiku T, Shinozaki A, Shibahara J, Iwasaki Y, Tateishi Y, Funata N, Fukayama M (2010) SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol 34:533–540. https://doi.org/10.1097/PAS.0b013e3181d1dcdd CrossRefPubMed

Ushiku T, Uozaki H, Shinozaki A, Ota S, Matsuzaka K, Nomura S, Kaminishi M, Aburatani H, Kodama T, Fukayama M (2009) Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas. Cancer Sci 100:626–632. https://doi.org/10.1111/j.1349-7006.2009.01108.x CrossRefPubMed

10.

Akazawa Y, Saito T, Hayashi T, Yanai Y, Tsuyama S, Akaike K, Suehara Y, Takahashi F, Takamochi K, Ueyama H, Murakami T, Watanabe S, Nagahara A, Yao T (2018) Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma. Hum Pathol. https://doi.org/10.1016/j.humpath.2018.04.022

11.

Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NG, Taylor AM, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749–1753CrossRefPubMed

12.

Nakamura Y (1998) ATM: the p53 booster. Nat Med 4:1231–1232. https://doi.org/10.1038/3207 CrossRefPubMed

13.

Li L, Li C, Mao H, Du Z, Chan WY, Murray P, Luo B, Chan AT, Mok TS, Chan FK, Ambinder RF, Tao Q (2016) Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci Rep 6:26591. https://doi.org/10.1038/srep26591 CrossRefPubMedPubMedCentral

14.

Chen Z, Shi X, Guo L, Li Y, Luo M, He J (2017) Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis. Oncotarget 8:1944–1952. https://doi.org/10.18632/oncotarget.13719 PubMedCrossRef

15.

Yang Q, Wu K, Ji M, Jin W, He N, Shi B, Hou P (2013) Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol 9:1607–1616CrossRefPubMed

16.

Li BT, Yu C, Xu Y, Liu SB, Fan HY, Pan WW (2017) TET1 inhibits cell proliferation by inducing RASSF5 expression. Oncotarget 8:86395–86409. https://doi.org/10.18632/oncotarget.21189 PubMedPubMedCentralCrossRef

17.

Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpcao PP, Bello MJ, Rey JA, Smith MA, Casartelli C (2008) Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res 41:539–543CrossRefPubMed

18.

Hurt EM, Thomas SB, Peng B, Farrar WL (2006) Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. Cancer Biol Ther 5:1154–1160CrossRefPubMed

19.

Gomes CC, Diniz MG, Orsine LA, Duarte AP, Fonseca-Silva T, Conn BI, De Marco L, Pereira CM, Gomez RS (2012) Assessment of TP53 mutations in benign and malignant salivary gland neoplasms. PLoS One 7:e41261. https://doi.org/10.1371/journal.pone.0041261 CrossRefPubMedPubMedCentral

20.

Okubo T, Saito T, Mitomi H, Takagi T, Torigoe T, Suehara Y, Kaneko K, Yao T (2013) p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1. Virchows Arch 463:67–77. https://doi.org/10.1007/s00428-013-1435-z CrossRefPubMed

21.

Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202–209. https://doi.org/10.1038/nature13480 CrossRef

22.

Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11:3471–3481CrossRefPubMedPubMedCentral

23.

Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674–1677CrossRefPubMed

24.

Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, Moas M, Buschmann T, Ronai Z, Shiloh Y, Kastan MB, Katzir E, Oren M (2001) ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 15:1067–1077. https://doi.org/10.1101/gad.886901 CrossRefPubMedPubMedCentral

25.

Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M, Kurman RJ (2011) Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 24:1248–1253. https://doi.org/10.1038/modpathol.2011.85 CrossRefPubMed

26.

Liao Y, Gu J, Wu Y, Long X, Ge DI, Xu J, Ding J (2016) Low level of 5-hydroxymethylcytosine predicts poor prognosis in non-small cell lung cancer. Oncol Lett 11:3753–3760. https://doi.org/10.3892/ol.2016.4474 CrossRefPubMedPubMedCentral

27.

Zhang Y, Wu K, Shao Y, Sui F, Yang Q, Shi B, Hou P, Ji M (2016) Decreased 5-hydroxymethylcytosine (5-hmC) predicts poor prognosis in early-stage laryngeal squamous cell carcinoma. Am J Cancer Res 6:1089–1098PubMedPubMedCentral

28.

Saldanha G, Joshi K, Lawes K, Bamford M, Moosa F, Teo KW, Pringle JH (2017) 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma. Mod Pathol 30:60–68. https://doi.org/10.1038/modpathol.2016.159 CrossRefPubMed

29.

Ciesielski P, Jozwiak P, Wojcik-Krowiranda K, Forma E, Cwonda L, Szczepaniec S, Bienkiewicz A, Brys M, Krzeslak A (2017) Differential expression of ten-eleven translocation genes in endometrial cancers. Tumour Biol 39:1010428317695017. https://doi.org/10.1177/1010428317695017 CrossRefPubMed

30.

Ichimura N, Shinjo K, An B, Shimizu Y, Yamao K, Ohka F, Katsushima K, Hatanaka A, Tojo M, Yamamoto E, Suzuki H, Ueda M, Kondo Y (2015) Aberrant TET1 methylation closely associated with CpG island methylator phenotype in colorectal cancer. Cancer Prev Res (Phila) 8:702–711. https://doi.org/10.1158/1940-6207.Capr-14-0306 CrossRef

31.

Tian Y, Pan F, Sun X, Gan M, Lin A, Zhang D, Zhu Y, Lai M (2017) Association of TET1 expression with colorectal cancer progression. Scand J Gastroenterol 52:312–320. https://doi.org/10.1080/00365521.2016.1253767 CrossRefPubMed

32.

Li Q, Yi B, Feng Z, Meng R, Tian C, Xu Q (2018) FAM20C could be targeted by TET1 to promote odontoblastic differentiation potential of human dental pulp cells. Cell Prolif 51:e12426. https://doi.org/10.1111/cpr.12426 CrossRefPubMed

Title: TP53 inactivation and expression of methylation-associated proteins in gastric adenocarcinoma with enteroblastic differentiation
Authors: Noboru Yatagai
Tsuyoshi Saito
Yoichi Akazawa
Takuo Hayashi
Yuka Yanai
Sho Tsuyama
Hiroya Ueyama
Takashi Murakami
Sumio Watanabe
Akihito Nagahara
Takashi Yao
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 3/2019
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2508-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

TP53 inactivation and expression of methylation-associated proteins in gastric adenocarcinoma with enteroblastic differentiation

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Donor-derived hepatocytes in human hematopoietic cell transplant recipients: evidence of fusion

AL amyloidosis with a localized B cell neoplasia

Clinicopathologic analysis and subclassification of benign lipomatous lesions of the colon

Mesothelin expression has prognostic value in stage ΙΙ/ΙΙΙ colorectal cancer

In this issue

Metastatic breast carcinoma to the urinary bladder—a report of 11 cases including a tumor to tumor metastasis